DELIVER at HFA: Heart Failure

The DELIVER team was proud to present at Heart Failure 2023 in Prague, Czech Republic. The following analyses were presented:

• Patient characteristics, outcomes, and effects of dapagliflozin according to the duration of heart failure: A prespecified analysis of the DELIVER trial presented by Toru Kondo

• Dapagliflozin and Diuretic Utilization in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction in the DELIVER Trial presented by Safia Chatur

• Effect of dapagliflozin on individual components of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial presented by Alexander Peikert

• Renal and Blood Pressure Effects of Dapagliflozin in Recently Hospitalized Patients with Heart Failure with Mildly Reduced or Preserved Ejection Faction: Insights from the DELIVER Trial presented by Safia Chatur

• Efficacy and safety of dapagliflozin in the background of polypharmacy among patients with HFmrEF or HFpEF in the DELIVER Trial presented by Alexander Peikert

• Cardio-Renal-Metabolic Overlap, Outcomes, and Treatment with Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction presented by John W. Ostrominski

• Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial presented by John W. Ostrominski

• Dapagliflozin in Patients With Heart Failure With and Without Peripheral Artery Disease: A patient-level pooled meta-analysis of DAPA-HF and DELIVER presented by Jawad Haider Butt

• Effect of Dapagliflozin on Health Status & Quality-of-Life Across the Spectrum of Ejection Fraction: from the DAPA-HF & DELIVER Trials presented by Ankeet S. Bhatt

• Effects of dapagliflozin on hospitalizations for heart failure according to severity of inpatient treatment course: Insights form DELIVER and DAPA-HF presented by Safia Chatur